Last reviewed · How we verify
NCT06683612
PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF
Phase 1 trial testing PIPE-791 in Idiopathic Pulmonary Fibrosis (IPF) in 16 participants. Completed in 12 June 2025.
4 June 2025
Quick facts
| Lead sponsor | Contineum Therapeutics |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 16 |
| Start date | 9 December 2024 |
| Primary completion | 4 June 2025 |
| Estimated completion | 12 June 2025 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- PIPE-791 — full drug profile →
Conditions studied
- Idiopathic Pulmonary Fibrosis (IPF) — all drugs for Idiopathic Pulmonary Fibrosis (IPF) →
- Idiopathic Pulmonary Fibrosis — all drugs for Idiopathic Pulmonary Fibrosis →
- Multiple Sclerosis — all drugs for Multiple Sclerosis →
- Multiple Sclerosis, MS — all drugs for Multiple Sclerosis, MS →
Sponsor
Contineum Therapeutics — full company profile →
Who can join
Adults 25 to 65, any sex, with Idiopathic Pulmonary Fibrosis (IPF) or Idiopathic Pulmonary Fibrosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a study of PIPE-791, an investigational study drug to treat progressive multiple sclerosis (MS) and idiopathic pulmonary fibrosis (IPF). The purpose of this study is to find out how much of the study drug gets into the brain and lung, and what the side effects and blood levels of the study drug are in healthy volunteers and patients. Participants will: * Take a single dose of the study drug * Give many samples of blood and urine * Have multiple PET scans
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Decoding lysophosphatidic acid signaling in physiology and disease: mapping the multimodal and multinodal signaling networks.
Nadhan R, Nath K, Basu S, Isidoro C, et al · · 2025 · cited 6× · PMID 41068071 · DOI 10.1038/s41392-025-02423-4 -
New Horizons for Multiple Sclerosis Therapy: 2025 and Beyond.
Sabatino JJ, Cree BAC, Hauser SL. · · 2025 · cited 5× · PMID 40474602 · DOI 10.1002/ana.27270 -
Recent Advances in Interventions Targeting Remyelination and a Systematic Review of Remyelinating Effects of Approved Disease-Modifying Treatments for Multiple Sclerosis.
De Keersmaecker AV, van Doninck E, Wens I, El Ouaamari Y, et al · · 2025 · PMID 41216863 · DOI 10.1111/ene.70397 -
The LPAR1 antagonist, PIPE-791 produces antifibrotic effects in models of lung fibrosis.
Poon M, Lorrain K, Broadhead A, Stebbins K, et al · · 2025 · PMID 40887574 · DOI 10.1186/s12931-025-03340-4
Verify or expand the search:
- PubMed search for NCT06683612
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of PIPE-791
Trials testing the same drug.
- NCT06810245 — Study of PIPE-791 for Subjects With Chronic Osteoarthritis Pain or Chronic Low Back Pain · Phase 1 · completed
- NCT05983939 — Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of PIPE-791 and Food Effect in Healthy · Phase 1 · completed
Other recruiting trials for Idiopathic Pulmonary Fibrosis (IPF)
Currently open trials in the same condition.
- NCT07482917 — Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 Trial · NA · recruiting
- NCT07486206 — Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 Trial · NA · recruiting
- NCT06968845 — A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis · Phase 2 · recruiting
- NCT07466420 — Study on the Efficacy of Quercetin Intake in Patients With Fibrotic Interstitial Lung Diseases. · NA · recruiting
- NCT07464912 — A Adaptive Design Clinical Trial to Evaluate the Efficacy and Safety of TDI01 Suspension in the Treatment of Idiopathic · Phase 3 · recruiting
Other Contineum Therapeutics trials
Trials by the same sponsor.
- NCT06810245 — Study of PIPE-791 for Subjects With Chronic Osteoarthritis Pain or Chronic Low Back Pain · Phase 1 · completed
- NCT06083753 — Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis · Phase 2 · completed
- NCT05983939 — Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of PIPE-791 and Food Effect in Healthy · Phase 1 · completed
- NCT04941781 — PET Study to Determine the Relationship Between Plasma Concentrations and Muscarinic Type 1 Receptor (M1AChR) Occupancy · Phase 1 · completed
- NCT04725175 — Phase I Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of of PIPE-307 and Food Effect · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06683612 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Contineum Therapeutics
- Last refreshed: 6 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06683612.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing